NRX Pharmaceuticals, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-09-14 by NRX Pharmaceuticals for period ending 2026-09-08, citing Item 7.01 (Reg FD Disclosure) and Item 9.01 (Financial Statements/Exhibits). Filing lists 20 graphic exhibits but actual substantive disclosure text is not reproduced in this EDGAR index page. Specific business event, counterparties, amounts, and financial impact cannot be determined from the index alone.
Why this rating
Index page only; material event content unavailable. Cannot assess dollar/operational significance without accessing full exhibit text. Standard periodic disclosure procedure.
Extracted items
- 7.01 Reg FD disclosure
- 9.01 exhibits
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.